DrugPatentWatch Database Preview
Cubist Pharms Company Profile
What is the competitive landscape for CUBIST PHARMS, and what generic alternatives to CUBIST PHARMS drugs are available?
CUBIST PHARMS has six approved drugs.
There are twenty-one US patents protecting CUBIST PHARMS drugs.
Summary for Cubist Pharms
| US Patents: | 21 |
| Tradenames: | 6 |
| Ingredients: | 5 |
| NDAs: | 6 |
Drugs and US Patents for Cubist Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cubist Pharms Llc | ZERBAXA | ceftolozane sulfate; tazobactam sodium | POWDER;INTRAVENOUS | 206829-001 | Dec 19, 2014 | RX | Yes | Yes | 7,129,232 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | POWDER;INTRAVENOUS | 205436-001 | Jun 20, 2014 | RX | Yes | Yes | 8,420,676 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Cubist Pharms Llc | CUBICIN RF | daptomycin | POWDER;INTRAVENOUS | 021572-003 | Jul 6, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | |||||
| Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | TABLET;ORAL | 205435-001 | Jun 20, 2014 | RX | Yes | Yes | 7,816,379 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | POWDER;INTRAVENOUS | 205436-001 | Jun 20, 2014 | RX | Yes | Yes | 7,816,379 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Cubist Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;IV (INFUSION) | 021572-001 | Sep 12, 2003 | RE39071 | ➤ Try a Free Trial |
| Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | 5,250,542 | ➤ Try a Free Trial |
| Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;IV (INFUSION) | 021572-001 | Sep 12, 2003 | 5,912,226 | ➤ Try a Free Trial |
| Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-002 | Sep 12, 2003 | RE39071 | ➤ Try a Free Trial |
| Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-002 | Sep 12, 2003 | 5,912,226 | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for CUBIST PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 12 mg | ➤ Subscribe | 2017-06-16 |
| ➤ Subscribe | Tablets | 200 mg | ➤ Subscribe | 2015-05-27 |
| ➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2008-11-19 |
Non-Orange Book US Patents for Cubist Pharms
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 9,624,250 | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5- -hydroxymethyl oxazolidin-2-one dihydrogen phosphate | ➤ Try a Free Trial |
| 7,696,220 | Methods for the treatment or inhibition of ileus | ➤ Try a Free Trial |
| 8,883,986 | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof | ➤ Try a Free Trial |
| 8,728,796 | Tiacumicin production | ➤ Try a Free Trial |
| 9,662,397 | Lipopeptide compositions and related methods | ➤ Try a Free Trial |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Cubist Pharms Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Israel | 219891 | ➤ Try a Free Trial |
| Portugal | 1699784 | ➤ Try a Free Trial |
| European Patent Office | 2393808 | ➤ Try a Free Trial |
| Eurasian Patent Organization | 029090 | ➤ Try a Free Trial |
| New Zealand | 712289 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Cubist Pharms Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 943 | Luxembourg | ➤ Try a Free Trial | PRODUCT NAME: CEFTOLOZANE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, EN PARTICULIER UN SEL D'ACIDE SULFURIQUE (ZERBAXA); FIRST REGISTRATION: 20150922 |
| 684 | Luxembourg | ➤ Try a Free Trial | PRODUCT NAME: FIDAXOMICINE OU SON SEL PHARMACEUTIQUEMENT ACCEPTABLE. FIRST REGISTRATION: 20111207 |
| 2015032 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: TEDIZOLIDO FOSFATAS; REGISTRATION NO/DATE: EU/1/15/991 20150323 |
| 2015032,C1699784 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: TEDIZOLIDAS, PASIRINKTINAI ESTERIO PAVIDALU, YPAC FOSFATO ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/15/991 20150323 |
| 2015 00048 | Denmark | ➤ Try a Free Trial | PRODUCT NAME: TEDIZOLID, OPTIONALLY IN THE FORM OF AN ESTER, IN PARTICULAR A PHOSPHATE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TEDIZOLID PHOSPHATE; REG. NO/DATE: EU/1/15/991 20150325 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
